We identified one patient with a well-known truncating variant in CHEK2. Although CHEK2 variants have been proposed to predispose to ovarian cancer [23] and the c.1100delC variant has been previously reported in two Russian ovarian cancer patients [24], there is insufficient evidence at present to conclude that CHEK2 contributes to ovarian cancer risk as it does in breast cancer [24]. An additional missense variant of ATM in this patient was of uncertain clinical significance. Here, CHEK2 is linked to breast carcinoma.